Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag SARS-CoV-2, Influenza A/B, RSV Test Receives CE Mark

NEW YORK – Mobidiag said on Monday that it has received the CE mark for its Amplidiag Resp-4 molecular diagnostic test for the detection of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus.

The assay rapidly and simultaneously detects the viruses, which can cause similar symptoms, from one patient sample using nasopharyngeal swabs. It runs on the Mobidiag Amplidiag Easy PCR platform, which can process up to 46 samples in about three hours, Espoo, Finland-based Mobidiag said.

The firm said it is currently also developing Novodiag Resp-4, a molecular test using its Novodiag platform for the rapid, on-demand detection of SARS-CoV-2, influenza A/B virus, and RSV. That test will complement the Amplidiag Resp-4 test.

Mobidiag's Novodiag COVID-19 and Amplidiag COVID-19 PCR tests received CE-IVD marking last June.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.